Trevena Names Roberto Cuca SVP, CFO - Quick Facts

(RTTNews) - Trevena Inc., a clinical stage pharmaceutical company, Tuesday announced the appointment of Roberto Cuca as senior vice president and chief financial officer.

"Roberto's diverse experience in effectively transitioning both private and public healthcare companies through phases of rapid growth will be invaluable in assisting Trevena through its corporate and strategic evolution," said Maxine Gowen, chief executive officer of Trevena.

Cuca brings to Trevena nearly 20 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as treasurer and senior vice president, Finance at Endo Health Solutions Inc., a specialty healthcare company.

Trevena, based in King of Prussia, Pennsylvania, has built a pipeline of biased GPCR ligands to address unmet medical needs in cardiovascular, pain and other CNS conditions.

The lead drug in Trevena's portfolio, TRV027, is a first-in-class agent in Phase 2 testing for the treatment of acute heart failure. TRV027 is being developed by Trevena under a recently announced collaborative licensing option deal with Forest Laboratories Inc. (FRX).

Trevena's pipeline also includes a clinical stage mu-opioid biased ligand, TRV130, in development for post-operative pain, a pre-clinical program for chronic pain, and discovery-stage programs for pain and Parkinson's disease.

Trevena is backed by Alta Partners, Healthcare Ventures, NEA, Polaris, Forest Holdings and Yasuda Enterprise Development Co.